eli lilly and company retatrutide Inside the grey market for Retatrutide, Lilly’s newest GLP drug 💉, Eli Lilly Expands Into Infectious

The results could lead to broader indications, further reinforcing its value in addressing chronic metabolic diseases

We propose that liver-targeted TR agonists that are capable of uncoupling beneficial effects from deleterious effects could be tested in future clinical studies for the treatment of type 2 diabetes

In general, tirzepatide tends to produce similar rates of nausea but potentially different patterns of gastrointestinal effects due to its additional GIP receptor activity

Retatrutide is generally safe for adults who meet the eligibility criteria, but it is not recommended for people with certain medical conditions, such as thyroid cancer history or pancreatitis

Fortunately, there are options

Do not start, stop, or change any medication without consulting your doctor